Nextera is a drug and target discovery company offering a unique and novel approach for improved therapeutic intervention in the major disease areas autoimmunity, chronic inflammatory disorders and cancer. Our approach is to modulate the disease at the core of the escalating immune cascade translating to disease-specific treatment without compromising systemic immunity.
Our strategy is to discover new targets and develop cognate drugs together with partners. We want to address complex diseases and jointly develop therapies in major indications that today seem difficult to treat.
It all starts and ends with the patient – focused onto to diseased tissue and the underlying immune repertoires, Nextera brings the unique ability to decipher clinical material with the outlook of subsequent intervention.
Company Details
- Employees
- 16
- Founded
- -
- Address
- Oslo Innovation Center, Gaustadalléen 21,norway
- Phone
- +47 22 95 81 94
- in****@****tera.no
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.nextera.no/
- HQ
- Oslo
Nextera As Questions
Nextera As's helpline number is +47 22 95 81 94
Nextera As's website is http://www.nextera.no/
Nextera As's LinkedIn profile is https://no.linkedin.com/company/nextera-as
Nextera As has
16 employees.
View email and phone details for 16
employees at Nextera As.
Nextera As's industry is
Biotechnology Research
Nextera As's top competitors are
Nykode Therapeutics,
Ondosis,
Zelluna,
Accession Therapeutics Limited,
Clexbio,
Nadeno Nanoscience As,
Circio Holding Asa,
Node Pharma,
Curida,
Curida Diatec.
Nextera As's support email address is info@nextera.no
Nextera As's categories are Biotechnology Research
Nextera As's founding year is 2009
